Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 193

1.

New therapeutic options for immune thrombocytopenia.

Schipperus M, Fijnheer R.

Neth J Med. 2011 Nov-Dec;69(11):480-5. Review.

2.

Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.

Zaja F, Barcellini W, Cantoni S, Carpenedo M, Caparrotti G, Carrai V, Di Renzo N, Santoro C, Di Nicola M, Veneri D, Simonetti F, Liberati AM, Ferla V, Paoloni F, Crea E, Volpetti S, Tuniz E, Fanin R.

Am J Hematol. 2016 May;91(5):E293-5. doi: 10.1002/ajh.24341. Epub 2016 Apr 4.

PMID:
26910388
3.

Moving towards a new era in the management of chronic immune thrombocytopenia.

Wadenvik H, Olsson B.

Ann Hematol. 2010 Jul;89 Suppl 1:87-93. Epub 2010 Mar 26. Review.

PMID:
20339846
4.

Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP.

Mori M, Kato M, Koh K, Hanada R.

Rinsho Ketsueki. 2015 May;56(5):511-3. doi: 10.11406/rinketsu.56.511.

PMID:
26062675
5.

The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).

Mazza P, Minoia C, Melpignano A, Polimeno G, Cascavilla N, Di Renzo N, Specchia G.

Ann Hematol. 2016 Jan;95(2):239-44. doi: 10.1007/s00277-015-2556-z. Epub 2015 Nov 24.

PMID:
26596973
6.

Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.

Aoki T, Harada Y, Matsubara E, Suzuki T, Oyama T, Kasai M, Uchida T, Ogura M.

J Clin Pharm Ther. 2012 Dec;37(6):729-32. doi: 10.1111/j.1365-2710.2012.01353.x. Epub 2012 May 14.

PMID:
22583038
7.

Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.

Kuter DJ, Macahilig C, Grotzinger KM, Poston SA, Wang PF, Dawson KL, Ward M.

Int J Hematol. 2015 Mar;101(3):255-63. doi: 10.1007/s12185-014-1731-7. Epub 2015 Jan 14.

PMID:
25586660
8.

Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura.

Stasi R, Evangelista ML, Amadori S.

Drugs. 2008;68(7):901-12. Review.

PMID:
18457458
9.

Thrombopoietin-receptor agonists in haematological disorders: the Danish experience.

Gudbrandsdottir S, Frederiksen H, Hasselbalch H.

Platelets. 2012;23(6):423-9. doi: 10.3109/09537104.2011.634931. Epub 2011 Dec 20.

PMID:
22185370
10.

Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.

González KJ, Zuluaga SO, DaRos CV, Rodríguez PP, Martí AC.

Ann Hematol. 2017 Mar;96(3):507-508. doi: 10.1007/s00277-016-2896-3. Epub 2016 Dec 15. No abstract available.

PMID:
27975127
11.

Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia.

Mitchell WB, Pinheiro MP, Boulad N, Kaplan D, Edison MN, Psaila B, Karpoff M, White MJ, Josefsson EC, Kile BT, Bussel JB.

Am J Hematol. 2014 Dec;89(12):E228-34. doi: 10.1002/ajh.23832. Epub 2014 Sep 2.

12.

Romiplostim in chronic immune thrombocytopenic purpura.

Cersosimo RJ.

Clin Ther. 2009 Sep;31(9):1887-907. doi: 10.1016/j.clinthera.2009.09.013. Review.

PMID:
19843480
13.

Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.

Neunert C, Despotovic J, Haley K, Lambert MP, Nottage K, Shimano K, Bennett C, Klaassen R, Stine K, Thompson A, Pastore Y, Brown T, Forbes PW, Grace RF; Pediatric ITP Consortium of North America (ICON)..

Pediatr Blood Cancer. 2016 Aug;63(8):1407-13. doi: 10.1002/pbc.26003. Epub 2016 May 2.

PMID:
27135461
14.

Thrombopoietin: too much or too little.

Newland A.

Hematology. 2012 Apr;17 Suppl 1:S166-8. doi: 10.1179/102453312X13336169156816.

PMID:
22507811
15.

[New treatment options for primary immune thrombocytopenia].

Gudbrandsdottir S, Frederiksen H, Birgens HS, Nielsen CH, Nielsen OJ, Stentoft J, Hasselbalch HC.

Ugeskr Laeger. 2011 Jan 24;173(4):271-4. Danish.

PMID:
21262171
16.

TPO receptor agonist for chronic idiopathic thrombocytopenic purpura.

Zeng Y, Duan X, Xu J, Ni X.

Cochrane Database Syst Rev. 2011 Jul 6;(7):CD008235. doi: 10.1002/14651858.CD008235.pub2. Review.

PMID:
21735426
17.

Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.

Tsukamoto S, Nakaseko C, Takeuchi M, Kumagai K, Komatsu T, Tanaka H, Hara S, Koizumi M, Imai H, Yokota A, Takeuchi M, Inokuchi K, Matsuura Y, Aotsuka N, Wakita H.

Br J Haematol. 2013 Oct;163(2):286-9. doi: 10.1111/bjh.12483. Epub 2013 Jul 17. No abstract available.

PMID:
23862773
18.

Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim.

Piccin A, Amaddii G, Natolino F, Billio A, Cortelazzo S.

Blood Transfus. 2014 Jan;12 Suppl 1:s149-50. doi: 10.2450/2013.0289-12. Epub 2013 Apr 17. No abstract available.

19.

Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists.

Ghadaki B, Nazi I, Kelton JG, Arnold DM.

Transfusion. 2013 Nov;53(11):2807-12. doi: 10.1111/trf.12139. Epub 2013 Mar 3.

20.

Immune thrombocytopenia -- what are the new treatment options?

Hallam S, Provan D, Newland AC.

Expert Opin Biol Ther. 2013 Aug;13(8):1173-85. doi: 10.1517/14712598.2013.801451. Epub 2013 May 17. Review.

PMID:
23682685

Supplemental Content

Support Center